Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-29
2010-10-19
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S359100
Reexamination Certificate
active
07816390
ABSTRACT:
The invention is directed to compounds having the following structures:N-(3-ethoxyphenyl)-1,4-dihydro-6-ethoxy-7-(3-hydroxypropoxy)-1-methylindeno[1,2-c]pyrazole-3-amine;3-[3-(3-Bromo-phenylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol;or3-[3-(2-Chloro-pyridin-4-ylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol, and N-oxides, pharmaceutically acceptable salts, solvates, tautomers and stereochemical isomers thereof and the uses of such compounds as inhibitors of tubulin polymerization and for the treatment of solid tumors. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
REFERENCES:
patent: 5474765 (1995-12-01), Thorpe
patent: 5762918 (1998-06-01), Thorpe
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6776796 (2004-08-01), Falotico et al.
patent: 7196110 (2007-03-01), Ho et al.
patent: 2002/0016625 (2002-02-01), Falotico et al.
patent: WO 96/32907 (1996-10-01), None
patent: WO 03/097609 (2003-11-01), None
Vippagunta et al., “Crystalline Solid”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Guillory (in Brittain ed.), Polymorphism, etc.,NY: Marcel Dekker, Inc., 1999, 1-2, 183-226.
Gould, P., International J. Pharm. (1986), 33, pp. 201-217.
Berge et al., J. Pharm. Sci., (Jan. 1977), 66(1), pp. 1-19.
Libby P, “Vascular biology of atherosclerosis: overview and state of the art”, Am J Cardiol (2003), 91(3A), pp. 3A-6A.
Helisch A, Schaper W., Arteriogenesis: the development and growth of collateral arteries. Microcirculation, (2003),10(1), pp. 83-97.
Holz FG et al.,“Pathogenesis of lesions in late age-related macular disease”, Am J Ophthalmol. (2004), 137(3), pp. 504-510.
Schiele TM et. al.,“Vascular restenosis—striving for therapy.” Expert Opin Pharmacother. (2004), 5(11), pp. 2221-2232.
Thannickal VJ et al., Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy, Expert Opin Pharmacother. (2004), 5(8), pp. 1671-1686.
Cybulsky AV, “Growth factor pathways in proliferative glomerulonephritis”, Curr Opin Nephrol Hypertens (2000), 9(3), pp. 217-223.
Harris RC et al, “Molecular basis of injury and progression in focal glomerulosclerosis” Nephron (1999), 82(4), pp. 289-299.
Woolf AS et al., “Evolving concepts in human renal dysplasia”, J Am Soc Nephrol. (2004), 15(4), pp. 998-1007.
Grant MB et al.,“The role of growth factors in the pathogenesis of diabetic retinopathy”, Expert Opin Investig Drugs (2004), 13(10), pp. 1275-1293.
Sweeney SE , Firestein GS, Rheumatoid arthritis: regulation of synovial inflammation, Int J Biochem Cell Biol. (2004), 36(3), pp. 372-378.
Simpson WG, The calcium channel blocker verapamil and cancer chemotherapy. Cell Calcium. (1985), 6(6), pp. 449-467.
Ricci A, et. al., “Neurotrophins and neurotrophin receptors in human pulmonary arteries.” J Vasc Res. (2000), 37(5), pp. 355-363.
Kim H, et. al., “Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells”, J Biol Chem. (2004), 279(32), pp. 33538-33546.
Douma S, et. al., “Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB”, Nature. (2004), 430(7003), pp. 1034-1040.
Arnon et al., “Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy”, in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al. (eds.), pp. 243-256 (Alan R. Liss, Inc. 1985).
Hellstrom et al., “Antibodies for Drug Delivery”, in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-653 (Marcel Dekker, Inc. 1987).
Thorpe, “Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review”, in Monoclonal Antibodies '84: Biological and Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985).
Galemmo Robert A.
Johnson Dana L.
Maharoof Umar S. M.
Mei Jay M.
Tuman Robert W.
Janssen Pharmaceutica NV
Morris Patricia L
LandOfFree
N-substituted tricyclic 3-aminopyrazoles as anti-mitotic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-substituted tricyclic 3-aminopyrazoles as anti-mitotic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted tricyclic 3-aminopyrazoles as anti-mitotic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4168926